High-risk HPV type-specific clearance rates in cervical screening.
about
Human papillomavirus type 16 viral load measurement as a predictor of infection clearance.Human papillomavirus mRNA and p16 detection as biomarkers for the improved diagnosis of cervical neoplasia.HPV type-related chromosomal profiles in high-grade cervical intraepithelial neoplasia.Development of a bead-based multiplex genotyping method for diagnostic characterization of HPV infectionMucosal immunity in the female genital tract, HIV/AIDSPersistence, clearance and reinfection regarding six high risk human papillomavirus types in Colombian women: a follow-up study.Inference of type-specific HPV transmissibility, progression and clearance rates: a mathematical modelling approachImpact of vaccination on 14 high-risk HPV type infections: a mathematical modelling approach.Eight nucleotide substitutions inhibit splicing to HPV-16 3'-splice site SA3358 and reduce the efficiency by which HPV-16 increases the life span of primary human keratinocytes.Natural history of progression of HPV infection to cervical lesion or clearance: analysis of the control arm of the large, randomised PATRICIA study.A pilot analytic study of a research-level, lower-cost human papillomavirus 16, 18, and 45 test.Short-time repeat high-risk HPV testing by self-sampling for screening of cervical cancerPhysical state and viral load as predictive biomarkersfor persistence and progression of HPV16-positive cervical lesions: results from a population based long-term prospective cohort studyComparison of the Roche cobas® 4800 and Digene Hybrid Capture® 2 HPV tests for primary cervical cancer screening in the HPV FOCAL trial.The potential harms of primary human papillomavirus screening in over-screened women: a microsimulation studyHuman papillomavirus 'reflex' testing as a screening method in cases of minor cytological abnormalities.Evaluation of candidate methylation markers to detect cervical neoplasiaPatterns of persistent genital human papillomavirus infection among women worldwide: a literature review and meta-analysis.Performance of a polymer-based DNA chip platform in detection and genotyping of human papillomavirus in clinical samples.Methylation of human papillomavirus Type 16 CpG sites at E2-binding site 1 (E2BS1), E2BS2, and the Sp1-binding site in cervical cancer samples as determined by high-resolution melting analysis-PCR.Short term persistence of human papillomavirus and risk of cervical precancer and cancer: population based cohort study.Differential in vitro immortalization capacity of eleven (probable) [corrected] high-risk human papillomavirus typesHuman papillomavirus infection among male clients of female sex workers soliciting sex in brothels in Peru.hnRNP L controls HPV16 RNA polyadenylation and splicing in an Akt kinase-dependent manner.Distribution of human papilloma virus genotype prevalence in invasive cervical carcinomas and precancerous lesions in the Yangtze River Delta area, China.Projected cervical Cancer incidence in Swaziland using three methods and local survey estimates.Population-Wide Associations between Common Viral Pathogens and Self-Reported Arthritis: NHANES 2009-2012
P2860
Q33887322-349D5CCD-10F2-4A32-A339-86C62A555592Q33978458-AFFB8FE4-B92C-417E-8FC2-D33DA85DA825Q34138292-3F2FF63F-7DD8-4423-8CC2-53E4628FC4F4Q34185819-5600A323-9090-48EC-A333-314B1587CA3DQ34275424-BC860867-DC9C-4FD3-885A-CF7BA25B1384Q34467791-710D7507-7A24-45D0-8BCC-839B4D0B246FQ34490267-87977E16-9E67-465D-BCBD-E369B49DCDCEQ34979497-F7CB0D06-5AF7-4416-B2A7-A3BE949909ADQ34988558-59A95A00-A145-4D8C-970C-7401E25BD367Q35048280-7BE4D177-112A-4659-A158-8AC13EAF6A0BQ35163760-2AAA3994-36F3-4226-AC2F-FDAB090E9D6EQ35287748-F4B06B65-C237-4191-AEC9-9D0A3A3C071AQ35832915-1362D0FC-A64C-4E34-A859-EAE20B718846Q35870574-584C4727-4BF2-4C3C-80BD-721735966F1AQ36699005-A6C27BD7-3372-44D7-AC4D-35DE88B026D6Q36858251-897A7384-273D-4FD9-9A04-4E6C16E39583Q36951370-26AC5591-93FB-4EC0-B00E-26229735C833Q37001336-10FE56E5-8BD3-4F2A-A383-2EBA557E36B5Q37191617-4C541106-B394-4FEB-86B0-AE6926F615F3Q37264251-37A0D0C0-0B1A-4593-92D1-51869C76EFEFQ37281729-80578505-2FE9-40C7-9204-ABFE081D7276Q37547351-7C277CE8-AE78-4834-8681-ED897CD4CD81Q40107289-099D3B2D-3EF8-412C-933B-55D8F36E22FFQ47635199-8D19C326-BC9B-409D-9FDC-37A06DD3EF39Q54983149-58416DB9-611E-4D17-9CDC-371BAF2C58CAQ55438912-67FAD8DF-03D4-4DBB-B043-CAEDC34F9EF5Q58593862-46D94954-641A-44FE-860C-3A58BE98A18F
P2860
High-risk HPV type-specific clearance rates in cervical screening.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
High-risk HPV type-specific clearance rates in cervical screening.
@ast
High-risk HPV type-specific clearance rates in cervical screening.
@en
type
label
High-risk HPV type-specific clearance rates in cervical screening.
@ast
High-risk HPV type-specific clearance rates in cervical screening.
@en
prefLabel
High-risk HPV type-specific clearance rates in cervical screening.
@ast
High-risk HPV type-specific clearance rates in cervical screening.
@en
P2093
P2860
P356
P1476
High-risk HPV type-specific clearance rates in cervical screening.
@en
P2093
C J L M Meijer
F J van Kemenade
L Rozendaal
M C G Bleeker
N W J Bulkmans
P J F Snijders
POBASCAM Study Group
P2860
P2888
P304
P356
10.1038/SJ.BJC.6603653
P407
P577
2007-03-06T00:00:00Z